■ Sight Sciences announced positive clinical results from the first study of its OMNI Surgical System. Findings from the pilot study suggest the OMNI, which is dually indicated for the sequential ab-interno procedures of microcatheterization and transluminal viscodilation of Schlemm’s canal followed by transluminal trabeculotomy, may provide a favorable safety profile and significant long-term reductions in IOP and IOP-lowering medications.

The pilot study included 24 eyes from 19 consecutive patients with mild to moderate primary open-angle glaucoma who were treated with the OMNI Surgical System. The study was conducted at the Ophthalmology Clinic Postgraduate Centre of Medical Education in Warsaw, Poland.

Key findings include that canal viscodilation followed by trabeculotomy using the OMNI Surgical System with or without cataract surgery resulted in substantial IOP reduction and IOP-lowering medication reductions at 18 months. There was a mean of 40% IOP reduction (21.4 mmHg to 12.8 mmHg) at 18 months, and a mean of 41% medication reduction (2.9 meds to 1.7 meds) at 18 months. The most common adverse events were IOP spikes (9 eyes), hyphema (6 eyes), and fibrin in the anterior chamber (5 cases), all of which resolved in the first week after surgery. No eyes required additional surgical intervention to control IOP over the 18-month follow-up period.